Taken together, these studies underscore that concomitant ARID1A/B loss defines a highly aggressive group of undifferentiated endometrial cancers characterized by rapid disease progression and insensitivity to conventional platinum and taxane-based chemotherapy. This evidence concerns the gene ARID1A and endometrial cancer.